tbuckley/cabot-search huggingface dataset:
Errors in Author Affiliations
Journal: JAMA Network Open (2023)

European Alzheimer’s & Dementia Biobank Mendelian Randomization (EADB-MR) Collaboration; Jiao Luo, MD, PhD; Jesper Qvist Thomassen, PhD; Céline Bellenguez, PhD; Benjamin Grenier-Boley, MSc; Itziar de Rojas, MSc; Atahualpa Castillo, PhD; Kayenat Parveen, MSc; Fahri Küçükali, PhD; Aude Nicolas, PhD; Oliver Peters, MD; Anja Schneider, MD; Martin Dichgans, MD; Dan Rujescu, MD; Norbert Scherbaum, MD; Deckert Jürgen, MD; Steffi Riedel-Heller, MD; Lucrezia Hausner, PhD; Laura Molina Porcel, MD, PhD; Emrah Düzel, MD, PhD; Timo Grimmer, PhD; Jens Wiltfang, MD; Stefanie Heilmann-Heimbach, PhD; Susanne Moebus, PhD; Thomas Tegos, MD, PhD; Nikolaos Scarmeas, MD, PhD; Jordi Clarimon, PhD; Fermin Moreno, MD, PhD; Jordi Pérez-Tur, PhD; María J. Bullido, PhD; Pau Pastor, MD, PhD; Raquel Sánchez-Valle, MD, PhD; Victoria Álvarez, PhD; Mercè Boada, MD, PhD; Pablo García-González, MSc; Raquel Puerta, MSc; Pablo Mir, MD, PhD; Luis M. Real, PhD; Gerard Piñol-Ripoll, MD, PhD; Jose María García-Alberca, MD, PhD; Jose Luís Royo, PhD; Eloy Rodriguez-Rodriguez, MD, PhD; Hilkka Soininen, MD, PhD; Teemu Kuulasmaa, MSc; Alexandre de Mendonça, PhD; Shima Mehrabian, PhD; Jakub Hort, MD, PhD; Martin Vyhnalek, PhD; Sven van der Lee, MD, PhD; Caroline Graff, MD, PhD; Goran Papenberg, PhD; Vilmantas Giedraitis, PhD; Anne Boland, PhD; Delphine Bacq-Daian, PhD; Jean-François Deleuze, PhD; Gael Nicolas, MD, PhD; Carole Dufouil, PhD; Florence Pasquier, MD, PhD; Olivier Hanon, MD, PhD; Stéphanie Debette, MD, PhD; Edna Grünblatt, PhD; Julius Popp, MD; Luisa Benussi, PhD; Daniela Galimberti, PhD; Beatrice Arosio, PhD; Patrizia Mecocci, MD, PhD; Vincenzo Solfrizzi, MD, PhD; Lucilla Parnetti, MD, PhD; Alessio Squassina, PhD; Lucio Tremolizzo, MD, PhD; Barbara Borroni, MD; Benedetta Nacmias, PhD; Sandro Sorbi, PhD; Paolo Caffarra, MD; Davide Seripa, PhD; Innocenzo Rainero, MD, PhD; Antonio Daniele, MD, PhD; Carlo Masullo, MD; Gianfranco Spalletta, MD, PhD; Julie Williams, PhD; Philippe Amouyel, MD, PhD; Frank Jessen, MD; Patrick Kehoe, PhD; Magda Tsolaki, MD, PhD; Giacomina Rossi, PhD; Pascual Sánchez-Juan, MD, PhD; Kristel Sleegers, MD, PhD; Martin Ingelsson, MD, PhD; Ole A. Andreassen, MD, PhD; Mikko Hiltunen, PhD; Cornelia Van Duijn, PhD; Rebecca Sims, PhD; Wiesje van der Flier, PhD; Agustín Ruiz, MD, PhD; Alfredo Ramirez, PhD; Jean-Charles Lambert, PhD; Ruth Frikke-Schmidt, MD, DMSc, PhD
68Ga-Pentixafor PET/MRI for Treatment Response Assessment in Mantle Cell Lymphoma
Authors: Marius E. Mayerhoefer, Markus Raderer, Michael Weber, Wolfgang Lamm, Barbara Kiesewetter, Marcus Hacker, Lukas Nics, Stefan Schmitl, Doris Leithner, Hans-Juergen Wester, Alexander Haug
Journal: Clinical Nuclear Medicine (2023)

Purpose The aim of this study was to compare CXCR4 imaging with 68 Ga-pentixafor PET to MRI for treatment response assessment in patients with mantle cell lymphoma (MCL). Patients and Methods Twenty-two posttreatment 68 Ga-pentixafor PET/MRI scans of 16 patients (7 women and 9 men; mean age, 69.9 ± 7.9) with a total of 67 target lesions on baseline PET/MRI were analyzed. Rates of complete remission per lesion and per scan, according to MRI (based on lesion size) and 68 Ga-pentixafor PET (based on SUV decrease to lower than liver and blood pool uptake), were compared using McNemar tests. The t tests and Pearson correlation coefficients ( r ) were used to compare rates of change in lesion diameter products (DPs) on MRI, and standardized uptake values (SUV max , SUV mean ) on PET, relative to baseline. Results At interim PET/MRI, 18/32 (56.3%) target lesions met CR criteria on 68 Ga-pentixafor PET, and 16/32 (50.0%) lesions met size-based MRI criteria for CR ( P = 0.63). At end-of-treatment PET/MRI, 40/57 (70.2%) target lesions met 68 Ga-pentixafor PET criteria for CR, and 27/57 (47.4%) lesions met size-based MRI criteria for CR ( P = 0.021). Complete remission after treatment was observed more frequently on 68 Ga-pentixafor PET (11/22 scans, 54.5%) than on MRI (6/22 scans, 27.3%) ( P = 0.031). Rates of change did not differ significantly between lesion DP (−69.20% ± 34.62%) and SUV max (−64.59% ± 50.78%, P = 0.22), or DP and SUV mean (−60.15 ± 64.58, P = 0.064). Correlations were strong between DP and SUV max ( r = 0.71, P &lt; 0.001) and DP and SUV mean ( r = 0.73, P &lt; 0.001). Conclusions In MCL patients, 68 Ga-pentixafor PET may be superior for assessment of complete remission status than anatomic MRI using lesion size criteria, especially at the end of treatment.
Anthracycline-Free Protocol for Favorable-Risk Childhood ALL: A Noninferiority Comparison Between Malaysia-Singapore ALL 2003 and ALL 2010 Studies
Authors: Hany Ariffin, Edwynn Kean Hui Chiew, Bernice Ling Zhi Oh, Shawn Hsien Ren Lee, Evelyn Huizi Lim, Shirley Kow Yin Kham, Wan Ariffin Abdullah, Lee Lee Chan, Koon Mian Foo, Joyce Ching Mei Lam, Yiong Huak Chan, Hai Peng Lin, Thuan Chong Quah, Ah Moy Tan, Allen Eng Juh Yeoh
Journal: Journal of Clinical Oncology (2023)

To investigate whether, for children with favorable-risk B-cell precursor ALL (BCP-ALL), an anthracycline-free protocol is noninferior to a modified Berlin-Frankfurt-Muenster ALL-IC2002 protocol, which includes 120 mg/m2 of anthracyclines.Three hundred sixty-nine children with favorable-risk BCP-ALL (age 1-9 years, no extramedullary disease, and no high-risk genetics) who cleared minimal residual disease (≤0.01%) at the end of remission induction were enrolled into Ma-Spore (MS) ALL trials. One hundred sixty-seven standard-risk (SR) patients (34% of Malaysia-Singapore ALL 2003 study [MS2003]) were treated with the MS2003-SR protocol and received 120 mg/m2 of anthracyclines during delayed intensification while 202 patients (42% of MS2010) received an anthracycline-free successor protocol. The primary outcome was a noninferiority margin of 1.15 in 6-year event-free survival (EFS) between the MS2003-SR and MS2010-SR cohorts.The 6-year EFS of MS2003-SR and MS2010-SR (anthracycline-free) cohorts was 95.2% ± 1.7% and 96.5% ± 1.5%, respectively (P = .46). The corresponding 6-year overall survival was 97.6% and 99.0% ± 0.7% (P = .81), respectively. The cumulative incidence of relapse was 3.6% and 2.6%, respectively (P = .42). After adjustment for race, sex, age, presenting WBC, day 8 prednisolone response, and favorable genetic subgroups, the hazard ratio for MS2010-SR EFS was 0.98 (95% CI, 0.84 to 1.14; P = .79), confirming noninferiority. Compared with MS2003-SR, MS2010-SR had significantly lower episodes of bacteremia (30% v 45.6%; P = .04) and intensive care unit admissions (1.5% v 9.5%; P = .004).In comparison with MS2003-SR, the anthracycline-free MS2010-SR protocol is not inferior and was less toxic as treatment for favorable-risk childhood BCP-ALL.
Errors in Abstract, Results, and Table 1
Journal: JAMA Network Open (2023)

Yujie Liu, MBBS; Tingting Geng, PhD; Zhenzhen Wan, MPH; Qi Lu, MBBS; Xuena Zhang, MBBS; Zixin Qiu, MBBS; Lin Li, MBBS; Kai Zhu, MBBS; Liegang Liu, PhD; An Pan, PhD; Gang Liu, PhD
Association of Sickle Cell Disease With Racial Disparities and Severe Maternal Morbidities in Black Individuals
Authors: Nansi S. Boghossian, Lucy T. Greenberg, George R. Saade, Jeannette Rogowski, Ciaran S. Phibbs, Molly Passarella, Jeffrey S. Buzas, Scott A. Lorch
Journal: JAMA Pediatrics (2023)

Little is known about the association between sickle cell disease (SCD) and severe maternal morbidity (SMM).
Spatial Transcriptional Mapping Reveals Site-Specific Pathways Underlying Human Atherosclerotic Plaque Rupture
Authors: Jiangming Sun, Pratibha Singh, Annelie Shami, Ewelina Kluza, Mengyu Pan, Djordje Djordjevic, Natasha Barascuk Michaelsen, Cecilia Kennbäck, Nicole N. van der Wel, Marju Orho-Melander, Jan Nilsson, Ivan Formentini, Karin Conde-Knape, Esther Lutgens, Andreas Edsfeldt, Isabel Gonçalves
Journal: Journal of the American College of Cardiology (2023)
Effect of 2022 ACC/AHA/HFSA Criteria on Stages of Heart Failure in a Pooled Community Cohort
Authors: Reza Mohebi, Dongyu Wang, Emily S. Lau, Juhi K. Parekh, Norrina Allen, Bruce M. Psaty, Emelia J. Benjamin, Daniel Levy, Thomas J. Wang, Sanjiv J. Shah, John S. Gottdiener, James L. Januzzi, Jennifer E. Ho
Journal: Journal of the American College of Cardiology (2023)
Progression of Cardiac Abnormalities in Hutchinson-Gilford Progeria Syndrome: A Prospective Longitudinal Study
Authors: Flemming Javier Olsen, Leslie B. Gordon, Leslie Smoot, Monica E. Kleinman, Marie Gerhard-Herman, Sheila M. Hegde, Srinivasan Mukundan, Taylor Mahoney, Joseph Massaro, Sendy Ha, Ashwin Prakash
Journal: Circulation (2023)

utchinson-Gilford Progeria syndrome (HGPS) is an ultrarare systemic disorder that causes accelerated aging and premature death, often due to cardiovascular disease. 1,2Because of its rarity, the characterization of cardiac abnormalities has been limited to cross-sectional assessment of small cohorts, and data on the progression of these abnormalities are lacking. 3s a follow-up to our previous cross-sectional report, we evaluated longitudinal changes in cardiac abnormalities in patients with HGPS.
Occam’s Razor: Two Arrhythmias in a Single Heart?
Authors: Aviram Hochstadt, Michael Geist, Sami Viskin
Journal: Circulation (2023)

A 68-year-old man with arterial hypertension treated with verapamil but no evident heart disease presented with a 2-hour history of palpitations.His physical examination was normal except for a heart rate of 100 bpm.His ECG showed a fairly regular narrow complex tachycardia (Fig-ure 1).The P-P interval is 395 milliseconds (best seen in lead I), representing a regular atrial rate of 152 bpm, whereas the ventricular rate is "only" 100 bpm and fairly regular.What is the best explanation for this tachycardia involving a rapid rhythm in the atria and the ventricles at different rates?Please turn the page to read the diagnosis.
Overall Survival for Osimertinib Wows
Journal: Cancer Discovery (2023)

The final overall survival (OS) results for the ADAURA trial show that osimertinib reduces the risk of death by 51% in patients with EGFR-mutated non-small cell lung cancer. For stage II or IIIA disease, the 5-year OS was 85% in patients who received osimertinib and 73% in the control group. The findings were nearly identical when patients with stage IB tumors were included in the analysis.
Targeted Options for Glioma Looking Good
Journal: Cancer Discovery (2023)

Abstract According to the phase III INDIGO trial, vorasidenib, an IDH1/2 inhibitor, significantly benefited adults with IDH1/2-mutant low-grade gliomas, reducing progression risk and delaying the need for chemoradiotherapy. Meanwhile, in a pediatric low-grade glioma cohort of FIREFLY-1, a phase II trial, robust responses to the type II pan-RAF inhibitor tovorafenib were seen.
Utility of a Handheld, Single-Lead ECG Device for Diagnosis of Cardiac Arrhythmias
Authors: Samual Turnbull, Kartheek Garikapati, Richard G. Bennett, Timothy G. Campbell, Yasuhito Kotake, Rajiv Mahajan, Simone Marschner, Karen Byth, Clara K. Chow, Saurabh Kumar
Journal: Journal of the American College of Cardiology (2023)
Ventricular Arrhythmias Associated With Over-the-Counter and Recreational Opioids
Authors: Mori J. Krantz, Todd J. Rudo, Mark C.P. Haigney, Norman Stockbridge, Robert B. Kleiman, Michael Klein, David P. Kao
Journal: Journal of the American College of Cardiology (2023)

Epidemic increases in opioid deaths prompted policies limiting access to prescription opioids in North America. Consequently, the over-the-counter opioids loperamide (Imodium A-D) and mitragynine, the herbal ingredient in kratom, are increasingly used to avert withdrawal or induce euphoria. Arrhythmia events related to these nonscheduled drugs have not been systematically studied.In this study, we sought to explore opioid-associated arrhythmia reporting in North America.The U.S. Food and Drug Administration Adverse Event Reporting System (FAERS), Center for Food Safety and Applied Nutrition Adverse Event Reporting System (CAERS), and Canada Vigilance Adverse Reaction (CVAR) databases were searched (2015-2021). Reports involving nonprescription drugs (loperamide, mitragynine) and diphenoxylate/atropine (Lomotil) were identified. Methadone, a prescription opioid (full agonist), served as a positive control owing to its established arrhythmia risk. Buprenorphine (partial agonist) and naltrexone (pure antagonist), served as negative controls. Reports were classified according to Medical Dictionary for Regulatory Activities terminology. Significant disproportionate reporting required a proportional reporting ratio (PRR) of ≥2, ≥3 cases, and chi-square ≥4. Primary analysis used FAERS data, whereas CAERS and CVAR data were confirmatory.Methadone was disproportionately associated with ventricular arrhythmia reports (PRR: 6.6; 95% CI: 6.2-7.0; n = 1,163; chi-square = 5,456), including 852 (73%) fatalities. Loperamide was also significantly associated with arrhythmia (PRR: 3.2; 95% CI: 3.0-3.4; n = 1,008; chi-square = 1,537), including 371 (37%) deaths. Mitragynine demonstrated the highest signal (PRR: 8.9; 95% CI: 6.7-11.7; n = 46; chi-square = 315), with 42 (91%) deaths. Buprenorphine, diphenoxylate, and naltrexone were not associated with arrhythmia. Signals were similar in CVAR and CAERS.The nonprescription drugs loperamide and mitragynine are associated with disproportionate reports of life-threatening ventricular arrhythmia in North America.
Re: First-in-Human Study of the Radioligand 68Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma
Authors: Niklas Klümper, Markus Eckstein, Michael Hölzel, Ken Herrmann, Boris Hadaschik, Viktor Grünwald
Journal: European Urology (2023)
Making the Case for All-Oral, Shorter Regimens for Children with Drug-Resistant Tuberculosis
Authors: Sayalee Patankar, Andrea T. Cruz, Bianca Douglas-Jones, Anthony Garcia-Prats, Alexander Kay, Anja Reuter, H. Simon Schaaf, James A. Seddon, Sangeeta Sharma, Jeffrey Starke, Marcela Tommasi, Rina Triasih, Jennifer J. Furin
Journal: American Journal of Respiratory and Critical Care Medicine (2023)

"Making the Case for All-Oral, Shorter Regimens for Children with Drug-Resistant Tuberculosis." American Journal of Respiratory and Critical Care Medicine, 0(ja), pp.
Genetic Testing for Cancer Susceptibility
Authors: Zsofia K. Stadler, Deborah Schrag
Journal: JAMA (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Association of Homelessness With Rates of Diabetes Complications: A Population-Based Cohort Study
Authors: Ruchi Sharan, Kathryn Wiens, Paul E. Ronksley, Stephen W. Hwang, Gillian L. Booth, Peter C. Austin, Eldon Spackman, Li Bai, David J.T. Campbell
Journal: Diabetes Care (2023)

OBJECTIVE To estimate the rates of diabetes complications and revascularization procedures among people with diabetes who have experienced homelessness compared with a matched cohort of nonhomeless control subjects. RESEARCH DESIGN AND METHODS A propensity-matched cohort study was conducted using administrative health data from Ontario, Canada. Inclusion criteria included a diagnosis of diabetes and at least one hospital encounter between April 2006 and March 2019. Homeless status was identified using a validated administrative data algorithm. Eligible people with a history of homelessness were matched to nonhomeless control subjects with similar sociodemographic and clinical characteristics. Rate ratios (RRs) for macrovascular complications, revascularization procedures, acute glycemic emergencies, skin/soft tissue infections, and amputation were calculated using generalized linear models with negative binomial distribution and robust SEs. RESULTS Of 1,076,437 people who were eligible for inclusion in the study, 6,944 were identified as homeless. A suitable nonhomeless match was found for 5,219 individuals. The rate of macrovascular complications was higher for people with a history of homelessness compared with nonhomeless control subjects (RR 1.85, 95% CI 1.64–2.07), as were rates of hospitalization for glycemia (RR 5.64, 95% CI 4.07–7.81) and skin/soft tissue infections (RR 3.78, 95% CI 3.31–4.32). By contrast, the rates of coronary revascularization procedures were lower for people with a history of homelessness (RR 0.76, 95% CI 0.62–0.94). CONCLUSIONS These findings contribute to our understanding of the impact of homelessness on long-term diabetes outcomes. The higher rates of complications among people with a history of homelessness present an opportunity for tailored interventions to mitigate these disparities.
Association of COVID-19 and Development of Type 1 Diabetes: A Danish Nationwide Register Study
Authors: Bochra Zareini, Kathrine Kold Sørensen, Pia A. Eiken, Thea K. Fischer, Peter Lommer Kristensen, Maria Elisabeth Lendorf, Ulrik Pedersen-Bjergaard, Christian Torp-Pedersen, Rúna L.M. Nolsoe
Journal: Diabetes Care (2023)

To compare the incidence of type 1 diabetes (T1D) before and during the coronavirus disease 2019 (COVID-19) pandemic and determine whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated with T1D development.All Danish residents aged <30 years free of diabetes from 2015 to 2021 were included. Individuals were followed from 1 January 2015 or birth until the development of T1D, the age of 30, the end of the study (31 December 2021), emigration, development of type 2 diabetes, onset of any cancer, initiation of immunomodulating therapy, or development of any autoimmune disease. We compared the incidence rate ratio (IRR) of T1D using Poisson regression models. We matched each person with a SARS-CoV-2 infection with three control individuals and used a cause-specific Cox regression model to estimate the hazard ratio (HR).Among 2,381,348 individuals, 3,579 cases of T1D occurred. The adjusted IRRs for T1D in each quarter of 2020 and 2021 compared with 2015-2019 were as follows: January-March 2020, 1.03 (95% CI 0.86; 1.23); January-March 2021, 1.01 (0.84; 1.22), April-June 2020, 0.98 (0.80; 1.20); April-June 2021, 1.34 (1.12; 1.61); July-September 2020, 1.13 (0.94; 1.35); July-September 2021, 1.21 (1.01; 1.45); October-December 2020, 1.09 (0.91; 1.31); and October-December 2021, 1.18 (0.99; 1.41). We identified 338,670 individuals with a positive SARS-CoV-2 test result and matched them with 1,004,688 control individuals. A SARS-2-CoV infection was not significantly associated with the risk of T1D development (HR 0.90 [95% CI 0.60; 1.35]).There was an increase in T1D incidence during April-June 2021 compared with April-June 2015-2019, but this could not be attributed to SARS-CoV-2 infection.
Multiple-Organ Involvement of Malakoplakia Mimicking Malignant Neoplasms on 18F-FDG PET/CT
Authors: Benzheng Jiao, Shanshan Liu, Xiaobo Ma, Chinting Wong, Hongguang Zhao
Journal: Clinical Nuclear Medicine (2023)

Abstract Abdominal contrast-enhanced CT was performed in a 61-year-old man with difficulties of urination and defecation for 4 months, which revealed huge rectal masses involving multiple adjacent organs, suspected as malignant lesions. 18 F-FDG PET/CT was subsequently performed for staging. The images showed intense FDG uptake and slightly hyperdense masses involving rectum, bladder, prostate, left ureter, and the anterior abdominal wall at the level of the pelvic cavity. Histopathological examination confirmed the masses were due to malakoplakia, which displayed as abundant von Hansemann cells aggregated and infiltrated in lesions, with distinctive cytoplasmic inclusions termed Michaelis-Gutmann bodies.
Relapsing Polychondritis
Authors: Sing Hon Kwok, Frankie Choi
Journal: Clinical Nuclear Medicine (2023)

Abstract We present a 54-year-old woman with 3-month history of skin rash and bilateral hearing loss. Multiple investigations including biopsy failed to reveal the underlying diagnosis of relapsing polychondritis, until 18 F-FDG PET/CT demonstrated a characteristic FDG activity pattern—the oto-rhino-tracheobronchial triad. The patient was subsequently diagnosed to have relapsing polychondritis and received treatment. The second FDG PET/CT revealed a differential response in different disease sites, which prompted an escalation of treatment.
The human right to a healthy environment: implications for climate action
Authors: Jess Beagley
Journal: BMJ (2023)

The human right to a healthy environment: implications for climate action Failure to tackle the causes and impacts of climate change undermines the United Nations human right to a healthy environment writes Jess Beagley Jess Beagley policy leadThe final hours of COP27 saw a dramatic shift from entrenched gridlock to historical firsts.This included recognition of the human right to a clean, healthy, and sustainable environment in the outcome text 1 -called the Sharm el-Sheikh Implementation Plan.This was accompanied by a breakthrough commitment by the world's wealthiest nations (and highest cumulative emitters) to establish a fund to address climate impacts ("loss and damage") in vulnerable countries, 2 and an inaugural mention of "food" in a COP summary text. 3Meanwhile, despite support from 80 countries including island nations, Latin American countries, the European Union, India, and the United Kingdom, language on fossil fuel phase-out in the cover decision remained unimproved since COP26 in Glasgow, (i.e. the wording remains "phasedown of unabated 4 coal power").Now, governments prepare to meet in Bonn, Germany, for the annual interim negotiations intended to advance progress between COPs-that is, the 58th meeting of the UNFCCC Subsidiary Bodies, or "SB58."The outcomes of SB58, which will take place from 5-15th June, will provide the foundations for decisions taken at COP28 this December.